Całkowita i trwała regresja przetrwałego torbielowatego obrzęku plamki w przebiegu zapalenia błony naczyniowej po jednorazowym podaniu doszklistkowym afliberceptu u pacjenta uprzednio leczonego wielokrotnymi iniekcjami doszklistkowymi ranibizumabu i bewacyzumabu
Śwituła M. Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab. Klinika Oczna / Acta Ophthalmologica Polonica. 2015;117(1):31-34.
APA
Śwituła, M. (2015). Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab. Klinika Oczna / Acta Ophthalmologica Polonica, 117(1), 31-34.
Chicago
Śwituła, Marcin. 2015. "Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab". Klinika Oczna / Acta Ophthalmologica Polonica 117 (1): 31-34.
Harvard
Śwituła, M. (2015). Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab. Klinika Oczna / Acta Ophthalmologica Polonica, 117(1), pp.31-34.
MLA
Śwituła, Marcin. "Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 117, no. 1, 2015, pp. 31-34.
Vancouver
Śwituła M. Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab. Klinika Oczna / Acta Ophthalmologica Polonica. 2015;117(1):31-34.
